Table 1 Correlations between the onset of stage 3 AKI and the demographics and comorbidities of patients scheduled for aortic surgery.

Age (years)

58.4 ± 12.7

57 ± 15.3

59.8 ± 10

0.111 [− 0.39–0.19]†

0.469

Women

17 (37.7)

7 (33.3)

10 (41.7)

10.429 [0.42–4.83]

0.575

Obesity

6 (13.3)

3 (14.3)

3 (12.5)

1.167 [0.21–6.51]

0.864

Body mass index (kg/m²)

24.6 ± 4.7

23.7 ± 4.7

25.4 ± 4.6

0.184 [−0.45–0.12]†

0.227

Current smokers

18 (36)

7 (33.3)

11 (45.8)

0.500 [0.15–1.68]

0.269

Chronic obstructive pulmonary disease

10 (22.2)

4 (19)

6 (25)

0.706 [0.17–2.95]

0.641

Hypertension

33 (73.3)

18 (85.7)

15 (62.5)

3.600 [0.82–15.74]

0.082

Diabetes mellitus type II

3 (6.7)

2 (9.5)

1 (4.2)

2.421 [0.20–28.8]

0.484

Heart failure

9 (20)

4 (19)

5 (20.8)

0.894 [0.20–3.88]

0.885

Atrial fibrillation

4 (8.9)

0 (0)

4 (16.7)

0.488 [0.36–.067]

0.051

Myocardial infarction, history

5 (11.1)

2 (9.5)

3 (12.5)

0.737 [0.11–4.9]

0.758

Metallic aortic valve

4 (8.2)

2 (9.5)

2 (8.3)

1.158 [0.15–9.03]

0.892

Marfan syndrome

4 (8.2)

3 (14.3)

1 (4.2)

4.909 [0.45–53.27]

0.170

Stroke, history

5 (11.1)

3 (14.3)

2 (8.3)

1.833 [0.28–12.19]

0.537

Chronic kidney disease (eGFR < 60 ml/min/1.73 m²)

19 (42.2)

12 (57.1)

7 (29.2)

3.238 [0.94–11.12]

0.06

Aortobifemoral graft

12 (26.7)

5 (23.8)

7 (29.2)

0.759 [0.20–2.89]

0.693

Anticoagulation

13 (28.9)

4 (19)

9 (37.5)

0.392 [− 1–1.54]

0.18